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Abstract
Background: Risk-reducing salpingo-oophorectomy (RRSO) around the age of 40 is currently recommended to
BRCA1/2 mutation carriers. This procedure decreases the elevated ovarian cancer risk by 80–96 % but it initiates
premature menopause as well. The latter is associated with short-term and long-term morbidity, potentially affecting
quality of life (QoL). Based on recent insights into the Fallopian tube as possible site of origin of serous ovarian
carcinomas, an alternative preventive strategy has been put forward: early risk-reducing salpingectomy (RRS) and
delayed oophorectomy (RRO). However, efficacy and safety of this alternative strategy have to be investigated.
Methods: A multicentre non-randomised trial in 11 Dutch centres for hereditary cancer will be conducted.
Eligible patients are premenopausal BRCA1/2 mutation carriers after completing childbearing without (a history of)
ovarian carcinoma. Participants choose between standard RRSO at age 35–40 (BRCA1) or 40–45 (BRCA2) and
the alternative strategy (RRS upon completion of childbearing and RRO at age 40–45 (BRCA1) or 45–50 (BRCA2)). Women
who opt for RRS but do not want to postpone RRO beyond the currently recommended age are included as
well. Primary outcome measure is menopause-related QoL. Secondary outcome measures are ovarian/breast cancer
incidence, surgery-related morbidity, histopathology, cardiovascular risk factors and diseases, and cost-effectiveness.
Mixed model data analysis will be performed.
Discussion: The exact role of the Fallopian tube in ovarian carcinogenesis is still unclear. It is not expected that further
fundamental research will elucidate this role in the near future. Therefore, this clinical trial is essential to investigate RRS
with delayed RRO as alternative risk-reducing strategy in order to improve QoL.
Trial registration: ClinicalTrials.gov (NCT02321228)
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Background
BRCA germline mutations and ovarian cancer
Epithelial ovarian cancer is the most lethal malignancy
of the female genital tract. With respect to treatment
and prognosis, primary carcinomas of the ovaries, fallo-
pian tubes and peritoneum are considered one disease
entity often referred to as ‘ovarian carcinoma’. Women
with germline mutations in one of the two BRCA genes
are at increased risk of developing breast and ovarian
cancer. Cumulative breast cancer risks are estimated
57–65 % (95 % CIs: 44–78 %) for BRCA1 and 45–49 %
(95 % CIs: 31–57 %) for BRCA2 mutation carriers by
age 70, whereas cumulative ovarian cancer risks lie
around 39–40 % (95 % CIs: 18–54 %) and 11–18 %
(95 % CIs: 2.4–23 %) by the age of 70 for BRCA1 en
BRCA2, respectively [1, 2]. Ovarian carcinoma occurs at
younger age in BRCA1 mutation carriers than in BRCA2
mutation carriers or the general population (both
mean and median 51 versus 56 versus 60 years respect-
ively) [3]. In BRCA1/2 germline mutation carriers, ap-
proximately 65 % of all ovarian carcinomas are of the
serous subtype [4–6].
Risk-reducing salpingo-oophorectomy (RRSO)
In contrast to breast cancer surveillance, screening for
ovarian cancer has been highly ineffective [7–9]. Therefore,
the only intervention to reduce ovarian cancer risk is risk-
reducing salpingo-oophorectomy (RRSO), which decreases
ovarian cancer incidence by about 80–96 % [4, 10–12].
However, this effect might be underestimated due to stud-
ies that included women who underwent oophorectomy
alone and/or underwent surgery above the currently rec-
ommended age: 35–40 for BRCA1 and 40–45 for BRCA2
mutation carriers [4, 11, 13]. The residual risk of primary
peritoneal cancer after RRSO is approximately 1 %; how-
ever, it was also reported to be more than 4 % [10, 14–16].
RRSO is often laparoscopically performed at an outpa-
tients’ department. Serious surgical complications rates are
low [4, 17, 18]. Main adverse effects of RRSO are related to
premature surgical menopause, including short-term
effects like vasomotor symptoms (i.e. hot flushes), sleep
disturbances, vaginal dryness and sexual symptoms [4].
Long-term effects include osteoporosis, increased risk of
cardiovascular disease, cognitive impairment and increased
depressive and anxiety symptoms, although prospective
studies on these long-term effects in BRCA mutation car-
riers in particular are not available [4, 19–22]. Postsurgical
hormone replacement therapy (HRT) does not fully
alleviate climacteric and sexual symptoms [20, 23].
The reduction of breast cancer incidence by half achieved
by performing RRSO at premenopausal age [11, 12] has
recently become arguable [24–26] and therefore question-
able as motivation to undergo RRSO.
Role of Fallopian tube in “ovarian” carcinogenesis
Based on recent scientific insights, the Fallopian tube is
considered the most important site of origin of pelvic
high grade serous carcinoma nowadays [27–31]. It is
suggested that benign tubal epithelium can transform into
serous tubal intraepithelial carcinoma (STIC) or invasive
tubal carcinoma [32]. The (pre)malignant cells can exfoli-
ate from the tubal epithelial lining and migrate to the
ovary and abdominal cavity. This theory is based on sev-
eral findings. First, no clear precursor of ovarian cancer
has been found in the ovary itself. Second, earlier studies
showed the presence of STIC in 36–60 % of sporadic pel-
vic serous carcinomas [33–35] which harboured identical
mutation in the TP53 gene to the cells of concurrent pel-
vic serous carcinomas in 92 % [36]. Third, pelvic serous
carcinoma cells resemble tubal lining epithelium more
than ovarian surface epithelium [37]. Several investigators
focused on prophylactically removed Fallopian tubes of
germline BRCA1/2 mutation carriers, showing the pres-
ence of STIC in about 4 % (range 0–12 %) [14, 38–47];
nearly all STICs were localised in the tubal distal fimbrial
ends [34].
Innovative preventive strategy: risk-reducing salpingectomy
(RRS) with delayed oophorectomy (RRO)
The growing evidence of the role of the Fallopian tube
in the origin of serous ovarian carcinoma together with
the disadvantages of premature surgical menopause
caused by RRSO, underlie the need for an alternative
risk-reducing strategy. RRS upon completion of child-
bearing offers an early, potentially risk-reducing inter-
vention; however, it is still uncertain whether and to
what extent the risk of ovarian cancer will be reduced.
Furthermore, around 68 % of occult carcinomas are found
in tubes [48] and could now be detected at an early stage.
The main advantage of delaying subsequent RRO beyond
the currently recommended age will be postponement of
premature menopause and its effect on noncancer-related
morbidity and (menopause-related) quality of life (QoL).
Several authors previously suggested this innovative strat-
egy [48–50] and a feasibility study among both profes-
sionals and germline BRCA1/2 mutation carriers from our
group showed a broad national support to evaluate this
new strategy in a prospective study [51].
Objective
The aim of this study is to determine whether an in-
novative risk-reducing strategy, consisting of RRS upon
completion of childbearing with delayed RRO, results in
better menopause-related QoL without increase of ovar-
ian and breast cancer risk in germline BRCA1/2 muta-
tion carriers compared to standard treatment, consisting
of RRSO at currently recommended age.
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Methods/Design
Study design
We will perform a nationwide prospective non-randomised
multicentre trial in 11 hospitals with a department for her-
editary cancer. Eligible patients will have the opportunity to
choose for standard or innovative strategy. Women who
opt for RRS but do not want to postpone RRO beyond the
currently recommended age or are unsure about this at en-
rolment are included as well; however, they will not con-
tribute to the number of inclusions needed according to
the sample size calculation. See Fig. 1 for an overview of
the study design.
Although a randomised controlled trial would be the
preferred study design, an earlier published feasibility study
among healthcare professionals and germline BRCA1/2
mutation carriers showed that randomisation would
be an insurmountable barrier for participation in a
clinical study [51]. These women want to decide them-
selves on their risk-reducing strategy and it is therefore
unlikely that they will participate in a randomised con-
trolled trial. Taken this into account, a prospective non-
randomised design seems the most appropriate, letting
women the opportunity to decide for themselves.
In addition, a control group will be formed by women
who underwent RRSO between 1 and 5 years ago, in
order to compare QoL between study participants and




Eleven hospitals with a hereditary cancer department
will participate in this study, of which seven are
university tertiary hospitals.
b. Patients
Women carrying a documented germline BRCA1/2
mutation from the department of Clinical Genetics
or Hereditary Cancer of each hospital, who are
between 25 and 40 (BRCA1) or 45 (BRCA2) years
old without previous RRSO.
Inclusion criteria
 Premenopausal women with a documented
BRCA1 and/or BRCA2 gene germline mutation
 Age 25–40 years for BRCA1 mutation carriers
and 25–45 years for BRCA2
 Childbearing completed
 Presence of at least one Fallopian tube




 Postmenopausal status (natural menopause or
due to (cancer) treatment)
 Wish for second stage RRO within two years
after RRS (if clear at enrolment)
 Legally incapable
Fig. 1 TUBA study design
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 Prior bilateral salpingectomy
 A personal history of ovarian, Fallopian tube or
peritoneal cancer
 Evidence of malignant disease at enrolment
 Current treatment for malignant disease
 Inability to read or speak Dutch
c. Patient recruitment
Eligible women will be sent a letter to inform them
on this study. BRCA1/2 mutation carriers will be
asked to respond whether or not they would be
interested to participate. If they are interested, the
patient information form will be sent and an
appointment will be made to explain the rationale,
design and aims of the study in person. The patient
will have sufficient time (minimal one week) to
consider the study before deciding to participate.
Written informed consent from the patient is
required before participation.
Furthermore, every newly diagnosed germline BRCA1/2
mutation carrier at the department of Clinical Genetics
that fulfills the inclusion criteria will be informed on the
study.
Outcome measures
a. Primary outcome measure
Menopause-specific QoL, measured by the Greene
Climacteric Scale (GCS) questionnaire in Dutch
[52]. This questionnaire consists of 21 items
divided into various domains: psychological (11
items, divided into anxiety and depression
subscales), somatic (7 items), vasomotor
symptoms (2 items) and sexual (1 item). Each
symptom is rated according to its severity using a
four-point Likert scale. The Greene Climacteric
score is the sum of all 21 items ranging from 0 to 63.
A higher total score corresponds with more
menopausal symptoms.
b. Secondary outcome measures
– General QoL and QoL-related items, mea-
sured by several questionnaires (see section
Pre-treatment evaluation)
– Incidence of ovarian and breast cancer
– Surgical complications, e.g. infection, conversion,
haemorrhage and complications at the second
laparoscopic procedure (RRO) due to previous
RRS.
– Histopathological findings of removed Fallopian
tubes and ovaries, i.e. (pre)malignancies
– Cardiovascular risk factors and incidence of
cardiovascular disease
– Cost-effectiveness of the innovative treatment
compared to standard treatment
Interventions
Standard treatment (control arm):
RRSO between age 35–40 in BRCA1 mutation carriers
and between 40–45 in BRCA2 mutation carriers (exact
ages varying across different hospitals) and when child-
bearing is completed.
Innovative treatment (experimental arm):
RRS when childbearing is completed with second stage
RRO delayed for five years compared to the currently
recommended age for RRSO, i.e. at the age of 40–45 in
BRCA1 and 45–50 in BRCA2 mutation carriers. Regard-
ing the definitive contraception which is a result of RRS
and the age at which RRS is performed, women will be
counseled in a similar manner as women consulting the gy-
naecologist for sterilization. RRS will be performed accord-
ing to Leblanc et al. [53]. Whenever a (pre)malignancy is
found in the RRS specimen, RRO will be performed as
soon as possible, as well as additional surgery or treatment
if necessary, e.g. staging procedure.
Data collection
a. Pre-treatment evaluation
All patients will be asked to fill out web-based base-
line questionnaires. Questionnaires on demographic
data and medical history with a special focus on
cancer and cardiovascular risk factors are included.
Furthermore, QoL(−related) questionnaires include
Dutch versions of the Greene Climacteric Scale
(GCS) [52], SF-36 [54], EQ-5D-5 L [55], Cancer
Worry Scale (CWS) [56, 57], Female Sexual Function
Index (FSFI) [58, 59], Female Sexual Distress Scale
(FSDS) [59, 60] and Decisional Conflict Scale (DCS)
[61]. Questions based on the Institute of Medical
Technology Assessment Productivity Cost Ques-
tionnaire (iPCQ) [62] and the Medical Consump-
tion Questionnaire (iMCQ) [63] will be used to
collect data on productivity loss and health con-
sumption. Moreover, blood pressure, body mass
index and waist-hip ratio will be documented.
Fasting blood samples will be taken to measure
cardiovascular risk factors.
b. Follow-up
Six weeks after surgery, data on surgical complications
and histopathological findings are collected. The
Sectioning and Extensively Examining the FIMbriated
End (SEE-FIM) of the Fallopian Tube (SEE-FIM)
protocol will be used for the latter [64]. Follow-
up by web-based questionnaires as described at
baseline except for the Decisional Conflict Scale
is scheduled at 3 and 12 months after surgery.
At 1, 5 and 15 years follow-up, the Decision
Regret Scale (DRS) is added [65]. From one year
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after surgery, questionnaires will be sent biennially
until the end of follow-up (in case of only one surgery
in the standard treatment arm) or until undergoing
RRO (in the innovative arm). After RRO, data
will be collected at six weeks and 3 and
12 months after surgery, comparable to follow-up
after the first operation, and then biennial question-
naires will be sent until the end of follow-up, 15 years
after the last (or only) surgery. Additionally, blood
pressure, body mass index, waist-hip ratio and
cardiovascular risk factors in fasting blood samples
will be collected five years after each surgery. Follow-
up by questionnaires will continue biennially until
15 years after the last surgery to detect occurrence of
ovarian cancer. Since the wide possible range of age
at inclusion, timing of surgeries and interval between
surgeries, it is hard to specify and generalize the exact
amount and timing of follow-up. A flowchart
visualising the follow-up schedule can be found in
Fig. 2.
c. Cost-effectiveness
This economic evaluation will compare costs and
quality adjusted life years (QALY) of the innovative
treatment with standard treatment. The perspective
of this economic evaluation will be a societal
perspective. Both healthcare and societal costs
which can be related to this study will be assessed
until 15 years after last surgery. Costs are collected
on a per patient level. The incremental costs of
innovative care compared to standard care will
be based on the difference in costs between groups.
The healthcare costs, measured by the Medical
Consumption Questionnaire (iMCQ) tailored to this
context, will be calculated. Societal costs will be
calculated from a selection of the Productivity Cost
Questionnaire (iPCQ). The output or consequences
of both innovative and standard care will be
determined by measuring QoL before and during the
study. The SF-36 and EQ-5D-5 L will be used for this
analysis. The outcomes will be translated to a long-
time difference in QALY. Key variables will be varied
in a sensitivity analysis to evaluate their impact on the
Fig. 2 Schedule of follow-up in TUBA study
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incremental costs per QALY gained ratio. Including
the innovative strategy in future guideline recommen-
dations depends on the incremental cost per QALY.
As mentioned before, data will be collected until
15 years after last surgery. However, an interim
cost-effectiveness analysis will be performed after
eight years to provide information for proceeding
implementation. Recommendation for implemen-
tation will be based on the empirical cost data
completed with modelled costs over the remaining
period. Accuracy of this model will be evaluated at
the end of 15 years follow-up, when data collection
on the actual costs during the remaining seven years
will have been completed.
d. Potential adverse events
In the innovative treatment, BRCA1/2 mutation
carriers will undergo an additional laparoscopy.
Known complication rates for RRSO in a comparable
population vary from 0.6–5 % for major complications
(conversion, bladder or bowel injury, additional
surgery required) and 3.7–10 % for minor
complications (infection, bleeding, haematoma)
[17, 18, 42, 66]. Risks might be lower for RRS alone.
As mentioned before, data on surgery-related com-
plications will be collected six weeks after each
surgery.
Furthermore, the worst-case scenario is that RRS does
not reduce ovarian cancer risk at all. Then, the post-
ponement of RRO for five years might result in a higher
ovarian cancer incidence in the experimental arm. We
used a model to calculate the risk for interval ovarian
carcinoma when RRO is performed five years later than
the current guideline age. The risk to develop ovarian
carcinoma within these five years is estimated to be up to
1–2 % for BRCA1 mutation carriers and up to 0.5–1 % for
BRCA2 mutation carriers. Cancer incidence will be moni-
tored by questionnaires.
Statistical analysis
a. Sample size calculation
The primary outcome measure is menopause-specific
QoL. Menopausal symptoms will be assessed by the
Greene Climacteric Scale (GCS). The main compari-
son is the difference in GCS between women getting
the innovative treatment and women getting standard
RRSO without postsurgical hormone replacement
therapy (HRT), which is about one third of women
after RRSO.
This difference is estimated at five points on the GCS,
with standard deviation 7.36, based on figures of
Barentsen et al. [67]. Each hospital will provide
both innovative and standard treatment, based on
patient choice (no randomization). We assume an
intra-cluster correlation coefficient ≤ 0.10. When we
have about 10 hospitals, with 51 patients per hospital
(total n = 510), we expect that the majority of hospitals
(7 hospitals or more) will provide at least 3 patients
with the innovative treatment. The remaining
hospitals (3 or less) provide 51 patients with
standard treatment of whom 16 will be on RRSO
without HRT. This scenario gives an 80 % power
(alpha = 0.05).
b. Data analysis
To test differences between two subgroups on the
course of QoL since baseline, we will carry out a
mixed model analysis to accommodate for
hospital effects and repeated measurements. All
secondary outcome measures will be analysed
using mixed models in a similar manner. Cost-
effectiveness, as far as it concerns the empirical
data, is analyzed in a stochastic fashion using
bootstrapped regression based techniques (i.e.,
linear mixed model) adhering to the net benefit
framework.
c. Safety
An independent Data Safety Monitoring Board
(DSMB) is established, existing of three independent
experts who have no conflict of interest. This
committee will meet once a year to perform interim
analysis specifically with respect to safety. The DSMB
will report to the study coordinator and may
recommend changes in the conduct of the study
or even premature study termination.
Ethics
The study is conducted according to the principles of the
Declaration of Helsinki (2008) and to the Medical Re-
search Involving Human Subjects Act (Dutch: WMO).
The protocol has been medical-ethically approved to be
conducted in all 11 centres by the Medical-Ethical Com-
mittee of Arnhem-Nijmegen (NL 50048.091.14). The
participating centres are the Radboud university medical
center Nijmegen, Maastricht University Medical Centre,
Erasmus MC Cancer Clinic Rotterdam, Center for
Gynaecological Oncology Amsterdam (CGOA): location
Netherlands Cancer Institute/Antoni van Leeuwenhoek
Hospital and location Amsterdam Medical Center, Univer-
sity Medical Center Groningen, UMC Utrecht Cancer
Centre, Leiden University Medical Centre, Gynaecologic
Oncologic Center South: two locations of Elisabeth-
TweeSteden Hospital Tilburg and location Catharina
Hospital Eindhoven. Furthermore, the protocol is regis-
tered in Clinicaltrials.gov (NCT02321228). Written in-
formed consent is obtained from all patients before
enrolment.
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Discussion
In this study protocol, we describe a prospective non-
randomised multicentre trial in premenopausal BRCA
mutation carriers. We compare the standard strategy to re-
duce ovarian cancer risk, i.e. RRSO at recommended age
of 35–40 in BRCA1 and at recommended age of 40–45 in
BRCA2 mutation carriers, with an innovative risk-reducing
strategy. In this innovative strategy, early RRS is performed
upon completion of childbearing and subsequent RRO
is delayed for five years compared to the currently recom-
mended age for the standard strategy. The primary out-
come measure is menopause-related QoL. Secondary
outcome measures include safety (cancer incidence and
surgical complications), histopathological findings of sur-
gery specimens, cardiovascular risk factors and cost-
effectiveness.
Currently, there are two other ongoing studies investi-
gating different aspects of salpingectomy in germline
BRCA mutation carriers. A research group from Texas
investigates patient compliance with delayed oophorec-
tomy after having undergone prophylactic salpingectomy
(NCT01907789). They compare three regimens: ovarian
cancer screening (3 years follow-up), prophylactic salpin-
gectomy with delayed oophorectomy (4 years of follow-up
including 1 year after oophorectomy) and risk-reducing
salpingo-oophorectomy (1 year follow-up). QoL is mea-
sured as well. Like our study, they do not randomise. This
study focuses on another endpoint, i.e. whether BRCA
mutation carriers return for oophorectomy after earlier
salpingectomy. Duration of follow-up is adjusted to this
endpoint en is relatively short to assess the safety of RRS
with delayed RRO as it comes to cancer incidence and
non-cancer related morbidity. In our study, we focus on
QoL, and several subdomains of QoL are measured as
well. Nevertheless, our follow-up will not be ceased after
QoL data completion, but will be prolonged to guarantee
a close monitoring of cancer incidence and non-cancer re-
lated morbidity.
In a French study, BRCA mutation carriers who are
reluctant to RRSO because of onset of premature meno-
pause are offered a radical fimbriectomy as alternative
(NCT01608074). Primary outcome is the number of pelvic
serous carcinomas occurring between fimbriectomy and
menopause. Secondary outcomes are perioperative morbid-
ity, histopathologic findings of fimbriectomy specimens, in-
cidence of breast cancer and the rate of secondary
oophorectomy and associated morbidity.
In this study, fimbriectomy is only offered to women
who refuse RRSO and RRS will in principle not be
followed by RRO, while all women in our study eventually
undergo RRO (current uptake of RRSO among BRCA mu-
tation carriers is 95 % in the Netherlands). Furthermore,
in this French study BRCA mutation carriers have to be
older than 35 to be included. We include women from
25 years old, to optimize possible risk reduction by remov-
ing the Fallopian tubes as early as possible upon comple-
tion of childbearing. At last, the possible advantages of
preservation of the ovaries for QoL are not evaluated in
this fimbriectomy study, while this is the primary outcome
in our study.
In conclusion, the current standard RRSO at age 35–40
(BRCA1) or 40–45 (BRCA2) is highly effective in reducing
ovarian cancer incidence. However, consequent premature
surgical menopause comes with short- and long-term
noncancer-related morbidity and probably affects QoL.
New insights in the origin of serous pelvic cancer put the
Fallopian tube forward as target for alternative preventive
surgery. The extent of the role of the Fallopian tubes in
ovarian carcinogenesis remains uncertain. We expect that
early salpingectomy with delayed oophorectomy is a rea-
sonable alternative to preserve ovarian function towards
the age of natural menopause without a significant in-
crease in ovarian cancer incidence.
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